The data suggest that primary tumor resection does not improve overall survival, but chemotherapy does.
Researchers identified socioeconomic and demographic factors related to oral treatment adherence in patients with multiple myeloma.
The program was associated with significant reductions in patients’ length of stay in the ICU, ICU mortality, and in-hospital mortality.
The expansion of Medicaid eligibility was associated with a nearly 3-fold increase in the proportion of Medicaid-covered patients enrolled in cancer treatment trials.
The G8 and CARG chemotherapy toxicity assessment tools were found to predict early hospitalization/ER visits and death in older patients with cancer.
Researchers identified demographic and socioeconomic factors associated with differences in staging of non-small cell lung cancer at initial presentation.
Having a high-deductible health plan was associated with a nearly 5-month delay in the diagnosis of metastatic cancer.
Patients who received denosumab had a significant improvement in disease-free survival and bone metastasis-free survival.
The incidence of advanced lung cancer declined by 3 cases per 100,000 people per year in 2015-2018 relative to 2004-2014.
The overall response rate was 66.7%, and the median duration of response was 17.5 months.
Among patients with ER+/HER2+ breast cancer, the median survival after distant recurrence increased from 2.3 years in 2000 to 4.8 years in 2019.
Acupuncture was associated with improvements in symptoms and quality of life.
Gender balance in cancer surveys of patients with myeloproliferative neoplasms was found to have relatively little effect on survey outcomes.
There was no significant difference in survival outcomes with trabectedin or physician’s choice of chemotherapy.
Rivoceranib produced responses whether or not patients had received prior treatment with a VEGFR TKI.
Patients were stratified by programmed death ligand 1 status and randomly and evenly assigned to 3 treatment groups.
In all, 32 patients had a response, translating to an ORR of 66.7%.
The 3-drug strategy combines targeted therapy against BRAF (vemurafenib) and MEK (cobimetinib), and immunotherapy (atezolizumab).
The study population included patients aged 18 years and older who had histologically confirmed desmoplastic melanoma that was resectable.
The estimated 2-year RFS rate for patients with MPR was 93.3% (95% CI, 87.2%-99.9%) after a median follow-up of 27.9 months.